Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Biovaxys Technology Corp
(CSE:
BIOV
)
0.2750
UNCHANGED
Streaming Delayed Price
Updated: 3:53 PM EDT, Oct 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.2750
Bid (Size)
0.2600 (10,000)
Ask (Size)
0.2900 (3,000)
Prev. Close
0.2750
Today's Range
0.2750 - 0.2750
52wk Range
0.0200 - 0.3100
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
InvestorNewsBreaks – BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB), SpayVac-for-Wildlife Inc. Expand License Agreement
April 22, 2025
Via
Investor Brand Network
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
September 20, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Performance
YTD
+358.3%
+358.3%
1 Month
-9.8%
-9.8%
3 Month
+1000.0%
+1000.0%
6 Month
+816.7%
+816.7%
1 Year
+323.1%
+323.1%
More News
Read More
BioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024
September 17, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
September 16, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
The Power Play by The Market Herald Releases New Interviews with Reunion Gold Corp, Numinus Wellness, Core Assets, Blockmate Ventures, BioVaxys Tech, Carlyle Commodities and Belmont Resources Discussing Their Latest News
April 18, 2023
Via
ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with Spey Resources, Melkior Resources and BioVaxys Technology Discussing Their Latest News
March 16, 2023
Via
ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with ApartmentLove, Sirios Resources, Aton Resources, Mountain Boy Minerals and BioVaxys Technology Discussing Their Latest News
December 20, 2022
Via
ACCESSWIRE
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
December 01, 2022
Via
FinancialNewsMedia
Topics
Intellectual Property
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
December 01, 2022
Via
FinancialNewsMedia
The Power Play by The Market Herald Releases New Interviews with RDARS, Infinity Stone Ventures, BioVaxys Technology, and Sitka Gold Discussing Their Latest News
October 06, 2022
Via
ACCESSWIRE
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
October 06, 2022
Via
FinancialNewsMedia
BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps
October 06, 2022
Via
FinancialNewsMedia
The Power Play by The Market Herald Releases a New Interview with BioVaxys Technology Discussing Their Latest News
September 28, 2022
Via
ACCESSWIRE
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
May 18, 2022
Via
FinancialNewsMedia
Topics
Death
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
May 18, 2022
Via
FinancialNewsMedia
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
April 25, 2022
Via
FinancialNewsMedia
Topics
Intellectual Property
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction
April 25, 2022
Via
FinancialNewsMedia
Topics
Economy
The Power Play by The Market Herald Releases Interviews With Monarch Mining, Vox, Tocvan Ventures, GeneTether Therapeutics, Peloton Minerals, SWMBRD Sports, and BioVaxys Technology Corp.
March 30, 2022
From
The Market Herald
Via
AccessWire
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
March 24, 2022
Via
FinancialNewsMedia
Biotech Sector’s Response to Omicron Panic Should be Swift and Effective
December 07, 2021
Via
FinancialNewsMedia
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
December 07, 2021
Via
FinancialNewsMedia
Covid-19 Test Shortage Emphasized by New $70M Plan to Speed Up Authorizations
November 09, 2021
Via
FinancialNewsMedia
Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030
November 09, 2021
Via
FinancialNewsMedia
Topics
Death
BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH
November 09, 2021
Via
FinancialNewsMedia
Faster, Cheaper, More Reliable COVID-19 Tests Needed for the Unprecedented Demand Ahead
October 20, 2021
Via
FinancialNewsMedia
Frequently Asked Questions
Is Biovaxys Technology Corp publicly traded?
Yes, Biovaxys Technology Corp is publicly traded.
What exchange does Biovaxys Technology Corp trade on?
Biovaxys Technology Corp trades on the Canadian Securities Exchange
What is the ticker symbol for Biovaxys Technology Corp?
The ticker symbol for Biovaxys Technology Corp is BIOV on the Canadian Securities Exchange
What is the current price of Biovaxys Technology Corp?
The current price of Biovaxys Technology Corp is 0.2750
When was Biovaxys Technology Corp last traded?
The last trade of Biovaxys Technology Corp was at 10/30/25 03:53 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
